Former Orbital scientists launch new mRNA therapy startupnews2026-05-06T15:17:04+00:00May 6th, 2026|Endpoints News|
J&J axes pair of CAR-T therapies for lymphoma, citing evolving marketnews2026-05-01T11:07:45+00:00May 1st, 2026|Endpoints News|
Lilly strikes second partnership this year for recombinase-based gene editingnews2026-04-28T11:00:57+00:00April 28th, 2026|Endpoints News|
Intellia’s in vivo CRISPR therapy first to succeed in Phase 3news2026-04-27T11:01:29+00:00April 27th, 2026|Endpoints News|
Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapynews2026-04-24T14:00:16+00:00April 24th, 2026|Endpoints News|
Lilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategynews2026-04-20T13:25:03+00:00April 20th, 2026|Endpoints News|
UCB plots epilepsy expansion with $650M Neurona cell therapy acquisitionnews2026-04-20T01:45:33+00:00April 20th, 2026|Endpoints News|
Three gene therapy pioneers just won the Breakthrough Prize. This is their storynews2026-04-18T23:13:44+00:00April 18th, 2026|Endpoints News|
#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standoutsnews2026-04-17T15:38:49+00:00April 17th, 2026|Endpoints News|
Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promisenews2026-04-13T15:25:50+00:00April 13th, 2026|Endpoints News|
